TABLE 1.
Baseline characteristics of the participants from the VDAART and COPSAC2010 prenatal vitamin D trials with genotype data stratified by intervention
| Characteristic | VDAART# | COPSAC2010¶ | ||||
|---|---|---|---|---|---|---|
| Placebo | Vitamin D | p-value | Placebo | Vitamin D | p-value | |
| Subjects n | 307 | 311 | 256 | 261 | ||
| rs12936231 | ||||||
| CC | 78 (25.4) | 93 (29.9) | 0.454 | 59 (23) | 62 (23.8) | 0.820 |
| GC | 161 (52.4) | 152 (48.9) | 126 (49.2) | 133 (51) | ||
| GG | 68 (22.1) | 66 (21.2) | 71 (27.7) | 66 (25.3) | ||
| Asthma/wheeze, 0–3 years | ||||||
| No | 215 (70) | 235 (75.6) | 0.146 | 206 (80.5) | 219 (83.9) | 0.364 |
| Yes | 92 (30) | 76 (24.4) | 50 (19.5) | 42 (16.1) | ||
| Sex | ||||||
| Male | 164 (53.4) | 157 (50.5) | 0.515 | 128 (50) | 141 (54) | 0.408 |
| Female | 143 (46.6) | 154 (49.5) | 128 (50) | 120 (46) | ||
| Race | ||||||
| Black | 146 (47.6) | 144 (46.3) | 0.359 | |||
| Caucasian | 92 (30) | 108 (34.7) | 256 (100) | 256 (100) | ||
| Other | 69 (22.5) | 59 (19) | ||||
| Serum vitamin D at age 3 years+ ng·mL−1 | 20.71±8.19 | 21.16±9.32 | 0.630 | |||
Data are presented as n (%) or mean±SD, unless otherwise indicated. VDAART: Vitamin D Antenatal Asthma Reduction Trial; COPSAC2010: Copenhagen Prospective Studies on Asthma in Childhood 2010.
#:
the total VDAART population was 806 children, data for 618 were included, the dose was 4400 IU daily in the intervention arm versus 400 IU in the placebo arm and was initiated in weeks 10–18;
¶:
the total COPSAC2010 population was 581, data for 517 were included, the dose was 2800 IU daily in the intervention arm versus 400 IU in the placebo arm and was initiated in weeks 22–26;
+:
available for VDAART only.